

Alla Guekht

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2955345/publications.pdf>

Version: 2024-02-01

95
papers

3,078
citations

136950

32
h-index

175258

52
g-index

103
all docs

103
docs citations

103
times ranked

4456
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-Suicidal Self-Injury in Russian Patients with Suicidal Ideation. Archives of Suicide Research, 2022, 26, 776-800.	2.3	13
2	Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System. Annals of Neurology, 2022, 91, 756-771.	5.3	78
3	Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports. Cephalalgia, 2022, 42, 1207-1217.	3.9	13
4	Not always that EASI: Validating the Russian version of the epilepsy anxiety survey instrument and its brief counterpart. Epilepsy and Behavior, 2022, 133, 108801.	1.7	4
5	Gamma Activity During Observation, Imagination, and Execution of Movements in Patients with Epilepsy: Invasive Study. Advances in Intelligent Systems and Computing, 2021, , 603-611.	0.6	1
6	A WHO resolution on epilepsy and other neurological disorders. Lancet Neurology, The, 2021, 20, 171-172.	10.2	8
7	The road to a World Health Organization global action plan on epilepsy and other neurological disorders. Epilepsia, 2021, 62, 1057-1063.	5.1	27
8	Interictal dysphoric disorder in people with and without epilepsy. Epilepsia, 2021, 62, 1382-1390.	5.1	2
9	Complementary and alternative medicine in epilepsy: A global survey of physicians'™ opinions. Epilepsy and Behavior, 2021, 117, 107835.	1.7	11
10	Validation of the Generalized Anxiety Disorder-7 (GAD-7) in Russian people with epilepsy. Epilepsy and Behavior, 2021, 123, 108269.	1.7	20
11	Brain-derived neurotrophic factor in blood serum and lacrimal fluid of patients with focal epilepsy. Epilepsy Research, 2021, 176, 106707.	1.6	5
12	Differential diagnosis between epileptic and psychogenic nonepileptic seizures through conversational analysis: A blinded prospective study in the Russian language. Epilepsy and Behavior, 2021, 125, 108441.	1.7	3
13	Validation of the Russian version of neurological disorders depression inventory for epilepsy (NDDI-E). Epilepsy and Behavior, 2020, 113, 107549.	1.7	6
14	How to understand and address the cultural aspects and consequences of diagnosis of epilepsy, including stigma. Epileptic Disorders, 2020, 22, 531-547.	1.3	24
15	A European questionnaire survey on epilepsy monitoring units' current practice for postoperative psychogenic nonepileptic seizures' detection. Epilepsy and Behavior, 2020, 112, 107355.	1.7	2
16	Testing blood and CSF in people with epilepsy: a practical guide. Epileptic Disorders, 2020, 22, 381-398.	1.3	12
17	The epidemiology of amyotrophic lateral sclerosis in Moscow (Russia). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 410-415.	1.7	7
18	Neuronal damage and neuroinflammation markers in patients with autoimmune encephalitis and multiple sclerosis. Metabolic Brain Disease, 2019, 34, 1473-1485.	2.9	24

#	ARTICLE	IF	CITATIONS
19	Prevalence of valproate prescriptions in women of childbearing age in certain regions of Russia. <i>Epilepsy and Behavior</i> , 2019, 101, 106584.	1.7	3
20	The Missing Link: How Exosomes and miRNAs can Help in Bridging Psychiatry and Molecular Biology in the Context of Depression, Bipolar Disorder and Schizophrenia. <i>Cellular and Molecular Neurobiology</i> , 2019, 39, 729-750.	3.3	52
21	Extensive validation study of the Parkinson's Disease Composite Scale. <i>European Journal of Neurology</i> , 2019, 26, 1281-1288.	3.3	8
22	Elevated Levels of Serum Exosomes in Patients with Major Depressive Disorder. <i>Neurochemical Journal</i> , 2019, 13, 385-390.	0.5	8
23	Acute stress response to a cognitive task in patients with major depressive disorder: potential metabolic and proinflammatory biomarkers. <i>Metabolic Brain Disease</i> , 2019, 34, 621-629.	2.9	21
24	Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. <i>Neurological Sciences</i> , 2018, 39, 629-640.	1.9	72
25	Transcranial direct current stimulation of 20- and 30-minutes combined with sertraline for the treatment of depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 82, 31-38.	4.8	31
26	Brain-Derived Neurotrophic Factor in Patients with Primary Open-Angle Glaucoma and Age-related Cataract. <i>Current Eye Research</i> , 2018, 43, 224-231.	1.5	43
27	Caspase Activity and Expression in Lymphocytes of Patients with Borderline Personality Disorders. <i>Neurochemical Journal</i> , 2018, 12, 270-274.	0.5	0
28	An Association Study of rs10462021 Polymorphism in the Clock Gene PERIOD3 and Different Clinical Types of Depression. <i>Molecular Genetics, Microbiology and Virology</i> , 2018, 33, 26-29.	0.3	1
29	Action Plan for Stroke in Europe 2018-2030. <i>European Stroke Journal</i> , 2018, 3, 309-336.	5.5	311
30	VaD - An Integrated Framework for Cognitive Rehabilitation. <i>CNS and Neurological Disorders - Drug Targets</i> , 2018, 17, 22-33.	1.4	7
31	Advocacy for children with epilepsy: Leveraging the WHA resolution. Advocacy Task Force, Commission of Pediatrics, International League Against Epilepsy. <i>Epilepsia Open</i> , 2018, 3, 167-174.	2.4	5
32	Epilepsy, Comorbidities and Treatments. <i>Current Pharmaceutical Design</i> , 2018, 23, 5702-5726.	1.9	16
33	Hair cortisol as a marker of hypothalamic-pituitary-adrenal Axis activity in female patients with major depressive disorder. <i>Metabolic Brain Disease</i> , 2017, 32, 577-583.	2.9	56
34	Current standards of neuropsychological assessment in epilepsy surgery centers across Europe. <i>Epilepsia</i> , 2017, 58, 343-355.	5.1	69
35	Epilepsy and treatment gap in urban and rural areas of the Southern Kazakhstan in adults. <i>Epilepsy and Behavior</i> , 2017, 67, 98-104.	1.7	12
36	Attitudes towards people with epilepsy in Moscow. <i>Epilepsy and Behavior</i> , 2017, 70, 182-186.	1.7	19

#	ARTICLE	IF	CITATIONS
37	ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin). <i>Stroke</i> , 2017, 48, 1262-1270.	2.0	71
38	The peptide-based drug cortexin inhibits brain caspase-8. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2017, 11, 134-138.	0.4	2
39	Letter by Vester et al Regarding Article, "Hope Dies Last" Evidence Again Fails to Support a Neuroprotectant: Cerebrolysin for Acute Ischemic Stroke. <i>Stroke</i> , 2017, 48, e365.	2.0	0
40	Educational needs of epileptologists regarding psychiatric comorbidities of the epilepsies: a descriptive quantitative survey. <i>Epileptic Disorders</i> , 2017, 19, 178-185.	1.3	18
41	Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. <i>Neurological Sciences</i> , 2017, 38, 1761-1769.	1.9	37
42	Caspase activity in lymphocytes of patients with depression and anxiety of different severity. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2017, 11, 76-80.	0.4	1
43	Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report. <i>BMC Medicine</i> , 2017, 15, 107.	5.5	77
44	Effects of cerebrolysin on nerve growth factor system in the aging rat brain. <i>Restorative Neurology and Neuroscience</i> , 2017, 35, 571-581.	0.7	16
45	Genetic Analysis of <i>BDNF</i> , <i>GNB3</i> , <i>MTHFR</i> , <i>ACE</i> and <i>APOE</i> Variants in Major and Recurrent Depressive Disorders in Russia. <i>International Journal of Medical Sciences</i> , 2016, 13, 977-983.	2.5	15
46	Current use of imaging and electromagnetic source localization procedures in epilepsy surgery centers across Europe. <i>Epilepsia</i> , 2016, 57, 770-776.	5.1	89
47	Activation of caspases in lymphocytes of patients with borderline personality disorders. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2016, 10, 246-250.	0.4	1
48	Current practices in long-term video-EEG monitoring services: A survey among partners of the E-PILEPSY pilot network of reference for refractory epilepsy and epilepsy surgery. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2016, 38, 38-45.	2.0	67
49	The direct costs of epilepsy in Russia. A prospective cost-of-illness study from a single center in Moscow. <i>Epilepsy and Behavior</i> , 2016, 64, 122-126.	1.7	12
50	Brain-derived neurotrophic factor in patients with age-related cataract. <i>Neurochemical Journal</i> , 2016, 10, 240-243.	0.5	1
51	Cerebrolysin and Recovery After Stroke (CARS). <i>Stroke</i> , 2016, 47, 151-159.	2.0	107
52	Free cortisol assessment in saliva: Saliva-to-serum ratio in depressed patients. <i>Neurochemical Journal</i> , 2015, 9, 315-318.	0.5	1
53	Ciliary neurotrophic factor in patients with age-related cataract. <i>Neurochemical Journal</i> , 2015, 9, 311-314.	0.5	1
54	In-hospital costs in patients with seizures and epilepsy after stroke. <i>Epilepsia</i> , 2015, 56, 1309-1313.	5.1	11

#	ARTICLE	IF	CITATIONS
55	The change in blood glucose level after a moderate stress as a parameter of stress reactivity in anxiety and depression: A pilot translational study. <i>Neurochemical Journal</i> , 2015, 9, 146-148.	0.5	2
56	From global campaign to global commitment: The World Health Assembly's Resolution on epilepsy. <i>Epilepsia</i> , 2015, 56, 1651-1657.	5.1	53
57	Technical approaches to a cortisol assay in hair for retrospective stress evaluation. <i>Neurochemical Journal</i> , 2015, 9, 73-75.	0.5	3
58	Neuroprotection in ischemic stroke: what does the future hold?. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 227-229.	2.8	14
59	Third International Congress on Epilepsy, Brain, and Mind: Part 2. <i>Epilepsy and Behavior</i> , 2015, 50, 138-159.	1.7	8
60	Post-stroke cognitive decline: an update and perspectives for clinical research. <i>European Journal of Neurology</i> , 2015, 22, 229.	3.3	184
61	Cognitive Dysfunction after On-Pump Operations: Neuropsychological Characteristics and Optimal Core Battery of Tests. <i>Stroke Research and Treatment</i> , 2014, 2014, 1-18.	0.8	18
62	Diabetes and the brain: issues and unmet needs. <i>Neurological Sciences</i> , 2014, 35, 995-1001.	1.9	44
63	Partial disconnection procedure in a patient with bilateral lesions (case report). <i>Epilepsy & Behavior Case Reports</i> , 2013, 1, 45-49.	1.5	4
64	Local epileptic activity, histological and neuroimaging findings in symptomatic epilepsy. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 371-383.	2.1	2
65	A single pentylenetetrazole-induced clonic-tonic seizure episode is accompanied by a slowly developing cognitive decline in rats. <i>Epilepsy and Behavior</i> , 2013, 26, 196-202.	1.7	28
66	Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2). <i>Epilepsy and Behavior</i> , 2013, 28, 283-302.	1.7	55
67	A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 459-467.	1.3	64
68	Current Perspectives in Post-stroke Cognitive Impairment. <i>European Neurological Review</i> , 2013, 8, 136.	0.5	1
69	Enzyme immunoassay for detection of protein-bound nitrotyrosine in brain tissue and cerebrospinal fluid: Methodological issues. <i>Neurochemical Journal</i> , 2012, 6, 239-245.	0.5	1
70	Health-related quality of life in Russian adults with epilepsy: The effect of socio-demographic and clinical factors. <i>Epilepsy and Behavior</i> , 2012, 25, 670-675.	1.7	40
71	Neuroprotection in vascular dementia: A future path. <i>Journal of the Neurological Sciences</i> , 2012, 322, 232-236.	0.6	33
72	Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. <i>Journal of the Neurological Sciences</i> , 2012, 322, 222-227.	0.6	44

#	ARTICLE	IF	CITATIONS
73	Seizures after stroke. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 108, 569-583.	1.8	16
74	Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia. Drugs of Today, 2012, 48, 25.	1.1	30
75	Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial. Journal of Stroke and Cerebrovascular Diseases, 2011, 20, 310-318.	1.6	45
76	Costs of illness and care in Parkinson's Disease: An evaluation in six countries. European Neuropsychopharmacology, 2011, 21, 180-191.	0.7	84
77	Indices of nitrosative stress and immune response in the liquor of patients at the early stage of stroke. Neurochemical Journal, 2011, 5, 73-75.	0.5	2
78	Some Characteristics of Emotional Disorders in Epilepsy. Neuroscience and Behavioral Physiology, 2011, 41, 68-73.	0.4	0
79	Convulsive Activity in the Electroencephalogram in Rats Sensitive and Tolerant to Pentylentetrazol Kindling. Neuroscience and Behavioral Physiology, 2010, 40, 239-244.	0.4	0
80	Acquisition of an Active Avoidance Reaction in Rats and Morphological Changes in the Hippocampus in Pentylentetrazol Kindling. Neuroscience and Behavioral Physiology, 2010, 40, 501-506.	0.4	3
81	The epidemiology of epilepsy in the Russian Federation. Epilepsy Research, 2010, 92, 209-218.	1.6	56
82	Long-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia, 2010, 51, 1963-1969.	5.1	92
83	Social and clinical determinants of quality of life in Parkinson's disease in a Russian cohort study. Parkinsonism and Related Disorders, 2010, 16, 243-248.	2.2	38
84	Placebo responses in randomized trials of antiepileptic drugs. Epilepsy and Behavior, 2010, 17, 64-69.	1.7	39
85	Costs of Illness in a Russian Cohort of Patients with Parkinson's Disease. Pharmacoeconomics, 2009, 27, 571-584.	3.3	35
86	Withdrawal of antiepileptic drugs in seizure-free patients: chance or jeopardy?. Nature Clinical Practice Neurology, 2008, 4, 598-599.	2.5	1
87	Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology, 2007, 69, 1610-1618.	1.1	60
88	Factors influencing on quality of life in people with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 128-133.	2.0	126
89	Current approaches to the use of generic antiepileptic drugs. Epilepsy and Behavior, 2007, 11, 46-52.	1.7	55
90	Polymorphism of apolipoprotein E (APOE) and lipoprotein lipase (LPL) genes and ischaemic stroke in individuals of Yakut ethnicity. Journal of the Neurological Sciences, 2007, 255, 42-49.	0.6	19

#	ARTICLE	IF	CITATIONS
91	Analgesic Efficacy and Safety of Lornoxicam Quick-Release Formulation Compared with Diclofenac Potassium. <i>Clinical Drug Investigation</i> , 2006, 26, 267-277.	2.2	29
92	Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 211-221.	1.5	21
93	The Provision of Epilepsy Care across Europe. <i>Epilepsia</i> , 2003, 44, 727-731.	5.1	26
94	Guidelines for the use of EEG methodology in the diagnosis of epilepsy. <i>Acta Neurologica Scandinavica</i> , 2002, 106, 1-7.	2.1	150
95	Quality of Life and the Stigma of Epilepsy. , 0, , 37-40.		1